Lp(a) is one of the most clinically meaningful — and most under-tested — cardiovascular risk factors in routine practice. Inaccurate assays, inconsistent reporting standards and disparities in testing across patient populations leave many at-risk patients undiagnosed and undertreated.
This on-demand session brings together two leading voices in Lp(a) science — from Mayo Clinic and NYU Langone — for a practical discussion of where current testing falls short and what high-performing programs are doing differently. The conversation moves from the structural and functional biology of lipoprotein(a) into case-based insights on integrating Lp(a) evaluation into cardiovascular risk assessment, plus a forward look at current and investigational therapies shaping the next phase of treatment.
Insights include:
-
Why current Lp(a) testing methods produce inaccuracies — and how to interpret results in practice
-
The disparities in Lp(a) testing across patient populations and where the gaps are widest
-
Real-world Lp(a) care processes from Mayo Clinic and NYU Langone
